Efficacy News and Research

RSS
ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

CareView Communications and IASIS Healthcare sign multi-hospital agreement

CareView Communications and IASIS Healthcare sign multi-hospital agreement

Commercial ultrasonic frequency devices are not effective in repelling insects

Commercial ultrasonic frequency devices are not effective in repelling insects

Cervical disc replacement: an interview with Joe Ross, VP of U.S. Marketing at LDR

Cervical disc replacement: an interview with Joe Ross, VP of U.S. Marketing at LDR

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Ibrutinib may effectively combat chronic lymphocytic leukemia

Ibrutinib may effectively combat chronic lymphocytic leukemia

Mesupron could extend progression-free survival for metastatic breast cancer patients

Mesupron could extend progression-free survival for metastatic breast cancer patients

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Iroko’s submicron indomethacin Phase 3 study on post-surgical acute pain meets primary endpoint

Iroko’s submicron indomethacin Phase 3 study on post-surgical acute pain meets primary endpoint

Novel antidepressant targets brain receptors responsible for learning and memory

Novel antidepressant targets brain receptors responsible for learning and memory

CBT may help reduce depression in people who have not responded to antidepressants

CBT may help reduce depression in people who have not responded to antidepressants

Weekly telephone contact with nurses reduces hospital re-admissions for high-risk patients

Weekly telephone contact with nurses reduces hospital re-admissions for high-risk patients

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

Using Nanoparticles to Target Cancer

Using Nanoparticles to Target Cancer

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Case Western Reserve to receive funding through Healthy Growth grant program

Case Western Reserve to receive funding through Healthy Growth grant program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.